Eastern Canadian Gastrointestinal Cancer Consensus Conference 2016. - Wikidata - awgldk - TriplyDB

Eastern Canadian Gastrointestinal Cancer Consensus Conference 2016.

Eastern Canadian Gastrointestinal Cancer Consensus Conference 2016.

http://www.wikidata.org/entity/Q37524976

about

Harnessing the mTOR Pathway for Tuberculosis Treatment.

P2860

Q49417693-35DE89D9-932F-4F92-8BC6-46A3AE4B01C7

P2860

Eastern Canadian Gastrointestinal Cancer Consensus Conference 2016.

http://www.wikidata.org/entity/Q37524976

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 21 December 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Eastern Canadian Gastrointestinal Cancer Consensus Conference 2016.

@en

Eastern Canadian Gastrointestinal Cancer Consensus Conference 2016.

@nl

type

label

Eastern Canadian Gastrointestinal Cancer Consensus Conference 2016.

@en

Eastern Canadian Gastrointestinal Cancer Consensus Conference 2016.

@nl

prefLabel

Eastern Canadian Gastrointestinal Cancer Consensus Conference 2016.

@en

Eastern Canadian Gastrointestinal Cancer Consensus Conference 2016.

@nl

P1433

Q37524976-48255D4F-BF93-4500-8D0D-3AB43013F574

P1476

Q37524976-F7D55DDB-BA95-4ECD-9666-C11D4758D8D0

P2093

Q37524976-02FFE1DE-45F4-473D-A4CC-33B8AC6F5432

Q37524976-0E781AB4-A38D-4E9A-8627-D288CBD00B5D

Q37524976-28187689-2075-4136-9CF2-513D99651B59

Q37524976-29E54ADE-313F-4E0F-A321-38C11A119F66

Q37524976-2A98C41F-462E-4E44-81D5-E9DACB74ACB0

Q37524976-2F8CA023-F70B-4D6E-BF65-4091B3761D64

Q37524976-3F5AC54C-4D31-496D-BB89-1362F3F8CCF2

Q37524976-46545292-583F-47C9-96B5-AF08780BF9EB

Q37524976-4A76B8B7-AE94-4325-B68E-F6677627B8DB

Q37524976-4D9A7345-63CD-436A-8FF6-274BC26E4B63

P2860

Q37524976-0373A81D-5CEC-4684-BEE0-AFC4A1F6E781

Q37524976-099A79D0-29F3-4A11-BBEB-69107EFE17D3

Q37524976-0CFE45B5-A289-411C-817E-3344B7CADF2D

Q37524976-0D9352EB-19CF-4027-AE44-B1D74D47B9FC

Q37524976-0F385712-E84D-4C57-BE43-B6E5E661209D

Q37524976-1988BAC5-38C5-44E8-BB30-9E03DD6D484A

Q37524976-1F51A8F8-90C5-48C4-97B5-59020C5D7B88

Q37524976-24ADABCC-AB74-40F6-8B11-0186E11ACE69

Q37524976-272BD759-8198-48EA-924D-1E70D2ACFA72

Q37524976-2C4A55C9-6689-4DF8-B360-89535DDAAFC4

P304

Q37524976-D5FCB201-BC65-46FB-A117-A64A35DA20F1

P31

Q37524976-975B33DC-9AA8-4D37-8B09-0F6E9430D28A

P356

Q37524976-2AC70875-18D9-43AD-B1B6-6920053B33AB

P433

Q37524976-304BBD8F-76B9-496D-87F5-E5C43DC9F9DB

P478

Q37524976-13EA5EFB-19B0-4C11-A0C9-939AB5587925

P50

Q37524976-5ECAFEA0-F2C7-42D5-8499-09F03C10C0F5

Q37524976-7965E73A-79D0-4D00-9C3F-062479D1225E

Q37524976-C6444A9F-DB92-45A9-B117-289094F315B1

P577

Q37524976-81122DBC-A9F3-4B10-94BE-D7652CC643ED

P698

Q37524976-01059F7A-E216-4DE1-9C1B-2706FC1023DE

P932

Q37524976-0E820621-8CA4-47A6-8887-FBFCB1E1CD9A

P356

P1433

Current Oncology

P1476

Eastern Canadian Gastrointestinal Cancer Consensus Conference 2016

@en

P2093

A Alfakeeh

http://www.w3.org/2001/XMLSchema#string

A Mahmud

http://www.w3.org/2001/XMLSchema#string

B Colwell

http://www.w3.org/2001/XMLSchema#string

B Samson

http://www.w3.org/2001/XMLSchema#string

B Ward

http://www.w3.org/2001/XMLSchema#string

C Ahmad

http://www.w3.org/2001/XMLSchema#string

C Cripps

http://www.w3.org/2001/XMLSchema#string

E Ferland

http://www.w3.org/2001/XMLSchema#string

E Tsvetkova

http://www.w3.org/2001/XMLSchema#string

F Halwani

http://www.w3.org/2001/XMLSchema#string

P2860

Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma

Managing synchronous liver metastases from colorectal cancer: a multidisciplinary international consensus

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine

Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival

Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial

Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

Angiogenic blockade and radiotherapy in hepatocellular carcinoma.

P304

e605-e614

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3747/CO.23.3394

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P50

Dominick Bossé

Laura A. Dawson

P577

2016-12-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28050151

http://www.w3.org/2001/XMLSchema#string

P932

5176388

http://www.w3.org/2001/XMLSchema#string